Health Professional Radio - Podcast

Returning guest Dr. Scot Ebbinghaus discusses the recent (Jan 2020) FDA approval of Merck's KEYTRUDA® (pembrolizumab) for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma In situ with or without papillary tumors who are Ineligible for or have elected not to undergo cystectomy.